Hims & Hers Health is trading 6.3% up at €26.64 in the supplied October 1, 2026 price context, amid a rebound as investors reassessed the recent selloff; no company-specific catalyst is confirmed. - Coverage described the September 30 session’s gain as unrelated to a new company announcement. - Securities class-action notices related to the earlier FTC lawsuit were in the news, but reporting did not identify them as the cause of the rise. - Healthcare shares were weaker, so sector strength does not explain the move.